Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cybrexa 4 Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action represents the entirety of the company's active prosecution for its therapeutic innovations. In the Biotechnology & Pharmaceuticals sector, maintaining 1 pending office action requires careful management of USPTO deadlines to ensure that the intellectual property protection remains on track with clinical trials.
The prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This focus within 1 distinct art unit suggests that the technical scope of the application is highly specialized and does not cross into other technical disciplines. Because there is only 1 distinct examiner involved, the company's strategy is entirely dependent on the interpretation of a single individual at the patent office.
REYNOLDS, FRED H is the busiest examiner for the portfolio, currently managing 1 pending office action. Since this 1 pending office action is the only one currently active, the interactions with REYNOLDS, FRED H will determine the immediate success of the company's patent efforts. Practitioners should review the specific tendencies of REYNOLDS, FRED H to navigate the 1 pending office action effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18056117 | PEPTIDE CONJUGATES OF PEPTIDIC TUBULIN INHIBITORS AS THERAPEUTICS | REYNOLDS, FRED H | 98d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18056117 | PEPTIDE CONJUGATES OF PEPTIDIC TUBULIN INHIBITORS AS THERAPEUTICS | REYNOLDS, FRED H | 1658 | §103DP | Non-Final OA | 98d overdue | Pending | Nov 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCybrexa 4 Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred H Reynolds has the most, with 1 of Cybrexa 4 Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.